In summary, our findings indicate that a key regulatory role of NPAS2 in glucose metabolism of PCa cells, which presents novel insights to help understand the mechanisms of circadian dysfunction in PCa progression and find new target for treatment of this malignancy. This evidence concerns the gene NPAS2 and posterior cortical atrophy.